Discover ErythroMer™
KaloCyte is developing ErythroMer™, a dried, bio-inspired artificial red blood cell, to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable or in short supply.
There is a Critical Need
Blood loss is the leading cause of preventable death after trauma. However, stored blood products are at times unavailable (pre-hospital care, austere environments, underdeveloped countries), undesirable (risk of immune response), or in short supply to meet demand (mass casualty event).
Our mission at KaloCyte is to develop an innovative artificial red blood cell to meet this critical need.
Our focus is to develop ErythroMer, a dried, bio-inspired artificial red blood cell, which has the potential to transform how we currently treat patients who need transfusion when stored red blood cells are not an option. ErythroMer has the potential to save numerous lives in pre-hospital settings, on and off the battlefield.
Unique Collaboration
Through a unique collaboration, our founders combined their expertise in red blood cell (RBC) physiology, trauma care, transfusion medicine and nanotechnology to create ErythroMer. KaloCyte has demonstrated proof of concept for ErythroMer, a first-in-class nano-encapsulated human hemoglobin, which mimics in vivo the complex physiology of natural RBCs. It can be freeze-dried for long-term storage at ambient conditions.
Developmental Research
This developmental research enabled our team to successfully compete for $14M in NIH and DoD grants and raise over $5M in investor funding that will support ErythroMer development, optimization and testing, positioning KaloCyte to advance to first-in-human trials.
FEATURED ON
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by nearly $20M in federal grants and investor funding.